programs and events

UPCOMING EVENTS IN YOUR AREA ABOUT AMVUTTRA® (vutrisiran)

Learn about AMVUTTRA, a treatment for the polyneuropathy caused by hATTR amyloidosis in adults.

Find an event in your area.

Patient Educational Event

Virtual Program
October 29, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison Sue, joined by Patient Ambassador Art, treated with AMVUTTRA, and Chris Bell, RN, MSN, ACNP, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Philadelphia, Pennsylvania
November 04, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison Sue
Register

Patient Educational Event

Anchorage, AK Alaska
November 05, 2025
11:00 AM to 12:30 PM AKST
Hear from an Alnylam Patient Education Liaison, Stacey, joined by Patient Ambassador, Art, treated with AMVUTTRA.
Register

Patient Educational Event

Tacoma, Washington
November 06, 2025
6:00 PM to 7:30 PM PT
Hear from an Alnylam Patient Education Liaison, Stacey, joined by Patient Ambassador, Art, treated with AMVUTTRA, and Elizabeth Hushka, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Virtual Program
November 06, 2025
7:00 PM to 8:30 PM CT
Hear from an Alnylam Patient Education Liaison Angela, joined by Patient Ambassador Kelly, treated with AMVUTTRA, and Dr. Brett Sperry, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Grand Rapids, Michigan
November 11, 2025
6:30 PM to 8:00 PM ET
Hear from an Alnylam Patient Education Liaison, Teresa, joined by Patient Ambassador, Kelly, treated with AMVUTTRA, and Sita Swamy, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

South Easton, Massachusetts
November 12, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison Kathy, joined by Patient Ambassador Al, treated with AMVUTTRA, and Deborah, their spouse and caregiver, and Dr. Albert Hicks, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Albany, New York
November 13, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Sue
Register

Patient Educational Event

Sarasota, Florida
November 13, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Christine, joined by Patient Ambassador, Marty, treated with AMVUTTRA, and Dr. Elsy Navas, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

New York, New York
November 13, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Christopher, joined by Patient Ambassador, Art, treated with AMVUTTRA, and Jennifer Fox, CRNP, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Virtual Program
November 17, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison Joanna, joined by Patient Ambassador Marty, treated with AMVUTTRA, and Dr. Albert Hicks, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

New Haven, Connecticut
December 03, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Kathy, joined by Patient Ambassador, Al, treated with AMVUTTRA, and Deborah, their spouse and caregiver
Register

Patient Educational Event

Stamford, Connecticut
December 04, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Kathy, joined by Patient Ambassador, Kelly, treated with AMVUTTRA, and Jennifer Fox, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Naples, Florida
December 04, 2025
6:00 PM to 7:30 PM ET
Hear from an Alnylam Patient Education Liaison, Christine, joined by Patient Ambassador, Art, treated with AMVUTTRA, and Dr. Elsy Navas, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Virtual Program
December 04, 2025
8:00 PM to 9:30 PM ET
Hear from an Alnylam Patient Education Liaison, Stacey, joined by Patient Ambassador Gary, treated with AMVUTTRA, and Dr. David Hinchman, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Irving, Texas
December 13, 2025
12:00 PM to 1:30 PM CT
Hear from an Alnylam Patient Education Liaison Kathy, joined by Patient Ambassador Al, treated with AMVUTTRA, and Deborah, their spouse and caregiver, and Dr. Ahmad Jabbar, a healthcare professional experienced in the management of ATTR-CM
Register

Patient Educational Event

Virtual Program
December 16, 2025
5:00 PM to 6:30 PM CT
Hear from an Alnylam Patient Education Liaison, Karen, joined by Patient Ambassador, Kelly, treated with AMVUTTRA, and Amy Brownell, MSN, FNP-C, AACC, a healthcare professional experienced in the management of ATTR-CM
Register

IMPORTANT SAFETY INFORMATION

What are the most important things I should know about AMVUTTRA® (vutrisiran)?

AMVUTTRA can cause low vitamin A levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.  

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA were pain in the arms or legs, pain in the joints, shortness of breath, and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR‑CM) in adults to reduce heart-related death, hospital stays and urgent visits.
  • polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR‑PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Footer Waves Left Footer Waves Right